Impact of obinutuzumab alone and in combination for follicular lymphoma
Blood and Lymphatic Cancer: Targets and Therapy · 2017
DOI: 10.2147/blctt.s114173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2017. Verfasst von Maryam Sarraf Yazdy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA, bdc@georgetown.edu. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA, bdc@georgetown.edu.
Zitieren
APA
Sarraf Yazdy, M., & Cheson, B. D. (2017). Impact of obinutuzumab alone and in combination for follicular lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s114173
Vancouver
Sarraf Yazdy M, Cheson BD. Impact of obinutuzumab alone and in combination for follicular lymphoma. Blood and Lymphatic Cancer: Targets and Therapy. 2017. doi:10.2147/blctt.s114173
BibTeX
@article{SarrafYazdy2017,
author = {Sarraf Yazdy, Maryam and Cheson, Bruce D},
title = {Impact of obinutuzumab alone and in combination for follicular lymphoma},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2017},
doi = {10.2147/blctt.s114173}
}
EUVIMED